US20090062909A1 - Stent with polymer coating containing amorphous rapamycin - Google Patents

Stent with polymer coating containing amorphous rapamycin Download PDF

Info

Publication number
US20090062909A1
US20090062909A1 US11995685 US99568506A US2009062909A1 US 20090062909 A1 US20090062909 A1 US 20090062909A1 US 11995685 US11995685 US 11995685 US 99568506 A US99568506 A US 99568506A US 2009062909 A1 US2009062909 A1 US 2009062909A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
rapamycin
coating
stent
polymer
invention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11995685
Inventor
Doug Taylor
James DeYoung
Jim McCain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MiCell Technologies Inc
Original Assignee
MiCell Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02Inorganic materials
    • A61L31/022Metals or alloys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2002/821Ostial stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001Designing or manufacturing processes
    • A61F2240/002Designing or making customized prostheses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2420/00Materials or methods for coatings medical devices
    • A61L2420/08Coatings comprising two or more layers

Abstract

A coated coronary stent, comprising: a stainless steel sent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating.

Description

    BACKGROUND OF THE INVENTION
  • [0001]
    It is often beneficial to provide coatings onto substrates, such that the surfaces of such substrates have desired properties or effects. It is useful to coat biomedical implants to provide for the localized delivery of pharmaceutical or biological agents to target specific locations within the body, for therapeutic or prophylactic benefit. One area of particular interest is drug eluting stents (DES) that has recently been reviewed by Ong and Sermuys in Nat. Clin. Pract. Cardiovasc. Med., (December 2005), Vol 2, No 12, 647. Typically such pharmaceutical or biological agents are co-deposited with a polymer. Such localized delivery of these agents avoids the problems of systemic administration, which may be accompanied by unwanted effects on other parts of the body, or because administration to the afflicted body part requires a high concentration of pharmaceutical or biological agent that may not be achievable by systemic administration. The coating may provide for controlled release, including long-term or sustained release, of a pharmaceutical or biological agent. Additionally, biomedical implants may be coated with materials to provide beneficial surface properties, such as enhanced biocompatibility or lubriciousness.
  • [0002]
    Conventional solvent-based spray coating processes are generally hampered by inefficiencies related to collection of the coating constituents onto the substrate and the consistency of the final coating. As the size of the substrate decreases, and as the mechanical complexity increases, it grows increasingly difficult to uniformly coat all surfaces of a substrate.
  • [0003]
    What is needed is a cost-effective method for depositing inert polymers and pharmaceutical or biological agents, such as rapamycin onto a substrate, where the collection process is efficient, the coating produced is conformal, substantially defect-free and uniform, and the composition of the coating can be regulated.
  • SUMMARY OF THE INVENTION
  • [0004]
    The present invention provides a coated coronary stent comprising: a stainless steel sent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating. In one embodiment, the PBMA, PEVA and rapamycin are present in a ratio of about 1:1:1.
  • [0005]
    In one aspect, the invention provides coated stents, wherein rapamycin is in the form of particles having an average diameter from 2 nm to 500 nm.
  • [0006]
    In another aspect, the invention provides coated stents, wherein the rapamycin-polymer coating has a thickness of about 1 to about 30 microns. The coating is preferably substantially free of solvent residue.
  • [0007]
    In yet another aspect, the invention provides a coated stent, wherein the rapamycin-polymer coating is sintered in dense carbon dioxide at a temperature of about 40 C to about 60 C, whereby bulk properties and adhesion of the coating to the stent are improved without altering the quality of the rapamycin, PBMA or PEVA. Preferably, the rapamycin-polymer coating covers substantially the entire surface of the stent framework and/or the rapamycin-polymer coating is substantially free of aggregated particles.
  • [0008]
    In another aspect, the invention provides a stent coated with a polymer and rapamycin comprising: a stainless steel stent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating disposed on the stent framework, wherein the rapamycin-polymer coating comprises PBMA, PEVA; and rapamycin substantially uniformly dispersed within the rapamycin-polymer coating, wherein substantially all of rapamycin in the coating is in amorphous form, wherein disposing the coating is carried out by a spray coating process whereby rapamycin spray particles are formed by rapid expansion of a supercritical or near critical fluid mixture, and the rapamycin spray particles and the stent framework are oppositely charged so that the spray particles are electrostatically attracted to the stent framework. Preferably, the spray coating process is carried out under RESS condition. The supercritical or near critical fluid mixture preferably comprises PBMA, PEVA and rapamycin dissolved in dimethylether, chlorofluorocarbon, hydrofluorocarbon, carbon dioxide or mixtures thereof.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0009]
    The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
  • [0010]
    FIG. 1. Rapid Expansion of Supercritical Solutions (RESS) process equipment see C. Domingo et al, Journal of Supercritical Fluids 10, 39-55 (1997)
  • [0011]
    FIG. 2. Infrared spectra of each component and the spray coating mixture. Individual peaks for each component are labeled.
  • [0012]
    FIG. 3. Stents coated (top panel) and sintered under different conditions (lower two panels) with rapamycin, PEVA and PBMA. All stent surfaces are coated
  • [0013]
    FIG. 4. Infrared spectra with all components coated, before and after sintering. The spectra indicate that no damage is done to the coating during the sintering process.
  • [0014]
    FIG. 5. XRD for RESS sprayed and as received rapamycin. The RESS sprayed rapamycin does not show any diffraction peaks indicating the RESS sprayed material is in amorphous form
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0015]
    The present invention is explained in greater detail below. This description is not intended to be a detailed catalog of all the different ways in which the invention may be implemented, or all the features that may be added to the instant invention. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure, which do not depart from the instant invention. Hence, the following specification is intended to illustrate some particular embodiments of the invention, and not to exhaustively specify all permutations, combinations and variations thereof.
  • DEFINITIONS
  • [0016]
    As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.
  • [0017]
    “Compressed fluid” as used herein refers to a fluid of appreciable density (e.g., >0.2 g/cc) that is a gas at standard temperature and pressure. “Supercritical fluid”, “near-critical fluid”, “near-supercritical fluid”, “critical fluid”, “densified fluid” or “densified gas” as used herein refers to a compressed fluid under conditions wherein the temperature is at least 80% of the critical temperature of the fluid and the pressure is at least 50% of the critical pressure of the fluid. Examples of substances that demonstrate supercritical or near critical behavior suitable for the present invention include, but are not limited to carbon dioxide, isobutylene, ammonia, water, methanol, ethanol, ethane, propane, butane, pentane, dimethyl ether, xenon, sulfur hexafluoride, halogenated and partially halogenated materials such as chlorofluorocarbons, hydrochlorofluoro carbons, hydrofluorocarbons, perfluorocarbons (such as perfluoromethane and perfluoropropane, chloroform, trichloro-fluoromethane, dichloro-difluoromethane, dichloro-tetrafluoroethane) and mixtures thereof.
  • [0018]
    “Sintering” as used herein refers to the process by which the polymer or polymers form continuous coating by treatment of the coated substrate with a densified gas, compressed fluid, compressed gas, near critical fluid or supercritical fluid that is a non-solvent for both the polymer and the pharmaceutical agent and biological agents, but an agent that induces formation of continuous domains of polymer. Through the sintering process, the adhesion properties of the coating are improved to reduce flaking of detachment of the coating from the substrate during manipulation.
  • [0019]
    “Rapid Expansion of Supercritical Solutions” or “RESS” as used herein involves the dissolution of a polymer into a compressed fluid, typically a supercritical fluid, followed by rapid expansion into a chamber at lower pressure, typically near atmospheric conditions. The rapid expansion of the supercritical fluid solution through a small opening, with its accompanying decrease in density, reduces the dissolution capacity of the fluid and results in the nucleation and growth of polymer particles. The atmosphere of the chamber is maintained in an electrically neutral state by maintaining an isolating “cloud” of gas in the chamber. Carbon dioxide or other appropriate gas is employed to prevent electrical charge is transferred from the substrate to the surrounding environment.
  • [0020]
    “Electrostatically charged” or “electrical potential” or “electrostatic capture” as used herein refers to the collection of the spray-produced particles upon a substrate that has a different electrostatic potential than the sprayed particles. Thus, the substrate is at an attractive electronic potential with respect to the particles exiting, which results in the capture of the particles upon the substrate. i.e. the substrate and particles are oppositely charged, and the particles transport through the fluid medium of the capture vessel onto the surface of the substrate is enhanced via electrostatic attraction. This may be achieved by charging the particles and grounding the substrate or conversely charging the substrate and grounding the particles, or by some other process, which would be easily envisaged by one of skill in the art of electrostatic capture.
  • [0021]
    “Open vessel” as used herein refers to a vessel open to the outside atmosphere, and thus at substantially the same temperature and pressure as the outside atmosphere.
  • [0022]
    “Closed vessel” as used herein refers to a vessel sealed from the outside atmosphere, and thus may be at significantly different temperatures and pressures to the outside atmosphere. Rapamycin is an immunosuppressive lactam macrolide that is produced by Streptomyces hygroscopicus, and having the structure depicted in Formula:
  • [0000]
    Figure US20090062909A1-20090305-C00001
  • [0023]
    See, e.g., McAlpine, J. B., et al., J. Antibiotics (1991) 44: 688; Schreiber, S. L., et al., J. Am. Chem. Soc. (1991) 113: 7433; U.S. Pat. No. 3,929,992.
  • [0024]
    The present invention provides a coated coronary stent comprising: a stainless steel sent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating.
  • [0025]
    In one embodiment, the PBMA, PEVA and rapamycin are present in a ratio of about 1:1:1.
  • [0026]
    In another embodiment, the invention provides coated stents, wherein rapamycin is in the form of particles having an average diameter from 2 nm to 500 nm.
  • [0027]
    In another embodiment, the invention provides coated stents, wherein the rapamycin-polymer coating has a thickness of about 1 to about 30 microns. The coating is preferably substantially free of solvent residue.
  • [0028]
    In yet another embodiment, the invention provides a coated stent, wherein the rapamycin-polymer coating is sintered in dense carbon dioxide at a temperature of about 40 C to about 60 C, whereby bulk properties and adhesion of the coating to the stent are improved without altering the quality of the rapamycin, PBMA or PEVA. Preferably, the rapamycin-polymer coating covers substantially the entire surface of the stent framework.
  • [0029]
    The invention encompasses embodiments wherein the rapamycin-polymer coating is substantially free of aggregated particles.
  • [0030]
    The invention also provides a stent coated with a polymer and rapamycin comprising: a stainless steel stent framework coated with a primer layer of Parylene C; and a rapamycin-polymer polymer coating disposed on the stent framework, wherein the rapamycin-polymer coating comprises PBMA, PEVA; and rapamycin substantially uniformly dispersed within the rapamycin-polymer coating, wherein substantially all of rapamycin in the coating is in amorphous form, wherein disposing the coating is carried out by a spray coating process whereby rapamycin spray particles are formed by rapid expansion of a supercritical or near critical fluid mixture, and the rapamycin spray particles and the stent framework are oppositely charged so that the spray particles are electrostatically attracted to the stent framework. Preferably, the spray coating process is carried out under RESS condition. The supercritical or near critical fluid mixture preferably comprises PBMA, PEVA and rapamycin dissolved in dimethylether, chlorofluorocarbon, hydrofluorocarbon, carbon dioxide or mixtures thereof.
  • EXAMPLES
  • [0031]
    The following examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.
  • Example 1
  • [0032]
    The RESS process equipment used in the present studies is depicted in FIG. 1. This is a common design for a RESS apparatus see C. Domingo et al, Journal of Supercritical Fluids 10, 39-55 (1997).
  • [0033]
    A solution containing rapamycin that is saturated in a solvent or supersaturated in a solvent is sprayed at a flow rate sufficient to achieve flow into a chamber of known volume pressurized above ambient pressure and containing a coronary stent. The system temperature is held constant or allowed to vary so that any number of points in the phase diagrams of the solution or mixture or any of its individual components can be mapped in pressure-temperature, volume-pressure or pressure-volume space constituting liquid, gas or supercritical CO2 conditions. CO2 in any single phase or combination of phases flows through the chamber at a mass flow rate of 5 gm/min to some multiple of this flow rate. After a period of time ranging from seconds to minutes or hours have elapsed, the solute and solvent flow that is a solution of the therapeutic compound and suitable solvent for the chosen solute or solutes cease but CO2 flow continues for an additional period of time maintaining constant pressure during this period. After this time period, the pressure is dropped to atmospheric pressure. During the spray coating process the particles are attracted to the stent by charging the substrate oppositely to that of the sprayed particle charge by applying a voltage that is greater than 5000 V but less than the ionization potential of the most easily ionized component of the mixture. The particles may also traverse an electromagnetic field such that the field is used to guide the particle to a target.
  • Example 2
  • [0034]
    The ability to uniformly coat arterial stents with rapamycin with controlled composition and thickness using electrostatic capture in a rapid expansion of supercritical solution (RESS) experimental series has been demonstrated. This technique involves spraying an equal part mixture of the therapeutic compound such as rapamycin and polymers such as PBMA and PEVA using a spray coating and collection technique described herein. To determine coating composition, infrared spectroscopy was used to collect the spectrum of a silicon wafer chip coated simultaneously with an arterial stent (FIG. 2). Unique absorption bands were identified for each mixture component and band area was used as a metric to determine incorporation of each compound in the coating.
  • [0035]
    The individual bands used for compositional analysis were determined by spray coating Si wafer chips with each component separately. The coating thickness was determined gravimetrically and calculated from the density of the materials. It was assumed that the layer is fully dense. The thickness can be controlled by varying the spray time.
  • [0036]
    In the as sprayed state, the coating lacks strong adhesion to the substrate. Sintering the coated substrate (see FIG. 3) dramatically improves coating adhesion while leaving the components unaltered as the infrared spectra shown in FIG. 4 confirm. The coating is sintered in a supercritical carbon dioxide environment allowing mild sintering conditions to be used with temperature below 80 C.
  • [0037]
    FIG. 4 shows Infrared spectra with all components coated, before and after sintering. The spectra indicate that no damage is done to the coating during the sintering process. The spectra demonstrate that the sintering process does not adversely impact the coating since no new stretches appear in the after sintering spectrum.
  • [0038]
    FIG. 5 shows XRD data taken for an authentic rapamycin sample (as received rapamycin) and RESS sprayed rapamycin. The RESS sprayed rapamycin does not show any diffraction peaks indicating the RESS sprayed material is in amorphous form. In other words, the RESS sprayed rapamycin lacks any crystallinity as indicated by the absence of diffraction peaks in the XRD.
  • [0039]
    While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims (13)

  1. 1. A coated coronary stent, comprising:
    a stainless steel sent framework coated with a primer layer of Parylene C; and
    a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating.
  2. 2. The stent of claim 1, wherein PBMA, PEVA and rapamycin are present in a ratio of about 1:1:1.
  3. 3. The stent of claim 1, wherein rapamycin is in the form of particles having an average diameter from 2 nm to 500 nm.
  4. 4. The stent of claim 1, wherein said coating has a thickness of about 1 to about 30 microns.
  5. 5. The stent of claim 1, wherein said coating is substantially free of solvent residue.
  6. 6. The stent of claim 1, wherein the rapamycin-polymer coating is sintered in dense carbon dioxide at a temperature of about 50 C to about 60 C and a pressure below 1000 psig, whereby bulk properties and adhesion of the coating to said stent are improved without altering the quality of the rapamycin, PBMA or PEVA.
  7. 7. The stent of claim 1, wherein said rapamycin-polymer coating covers substantially the entire surface of said stent framework.
  8. 8. The stent of claim 1, wherein said rapamycin-polymer coating is substantially free of aggregated particles.
  9. 9. A stent coated with a polymer and rapamycin, comprising:
    a stainless steel stent framework coated with a primer layer of Parylene C; and
    a rapamycin-polymer coating disposed on the stent framework, wherein the rapamycin-polymer coating comprises PBMA, PEVA; and rapamycin substantially uniformly dispersed within the rapamycin-polymer coating, wherein substantially all of rapamycin in the coating is in amorphous form, wherein disposing said coating is carried out by a spray coating process whereby rapamycin spray particles are formed by rapid expansion of a supercritical or near critical fluid mixture, and said rapamycin spray particles and said stent framework are oppositely charged so that said spray particles are electrostatically attracted to said stent framework.
  10. 10. The stent of claim 9, wherein said spray coating process is carried out under RESS conditions.
  11. 11. The stent of claim 10, wherein said supercritical or near critical fluid mixture comprises PBMA, PEVA and rapamycin dissolved in dimethylether, chlorofluorocarbon, hydrofluorocarbon, carbon dioxide or mixtures thereof.
  12. 12. The stent of claim 10, wherein PBMA, PEVA and rapamycin are co-deposited from a single mixture.
  13. 13. The stent of claim 10, wherein PBMA, PEVA and rapamycin are separately deposited on the stent.
US11995685 2005-07-15 2006-07-14 Stent with polymer coating containing amorphous rapamycin Abandoned US20090062909A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US69965005 true 2005-07-15 2005-07-15
US76533906 true 2006-02-03 2006-02-03
PCT/US2006/027322 WO2007011708A3 (en) 2005-07-15 2006-07-14 Stent with polymer coating containing amorphous rapamycin
US11995685 US20090062909A1 (en) 2005-07-15 2006-07-14 Stent with polymer coating containing amorphous rapamycin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11995685 US20090062909A1 (en) 2005-07-15 2006-07-14 Stent with polymer coating containing amorphous rapamycin

Publications (1)

Publication Number Publication Date
US20090062909A1 true true US20090062909A1 (en) 2009-03-05

Family

ID=37669386

Family Applications (2)

Application Number Title Priority Date Filing Date
US11995685 Abandoned US20090062909A1 (en) 2005-07-15 2006-07-14 Stent with polymer coating containing amorphous rapamycin
US14718342 Pending US20160015537A1 (en) 2005-07-15 2015-05-21 Stent with polymer coating containing amorphous rapamycin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14718342 Pending US20160015537A1 (en) 2005-07-15 2015-05-21 Stent with polymer coating containing amorphous rapamycin

Country Status (2)

Country Link
US (2) US20090062909A1 (en)
WO (1) WO2007011708A3 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095919A1 (en) * 2006-10-23 2008-04-24 Mcclain James B Holder For Electrically Charging A Substrate During Coating
US20090123515A1 (en) * 2005-07-15 2009-05-14 Doug Taylor Polymer coatings containing drug powder of controlled morphology
US20090186069A1 (en) * 2006-04-26 2009-07-23 Micell Technologies, Inc. Coatings Containing Multiple Drugs
US20090292351A1 (en) * 2008-04-17 2009-11-26 Micell Technologies, Inc. Stents having bioabsorbable layers
US20100015200A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug Delivery Medical Device
US20100030261A1 (en) * 2006-10-02 2010-02-04 Micell Technologies, Inc. Surgical Sutures Having Increased Strength
US20100063580A1 (en) * 2007-01-08 2010-03-11 Mcclain James B Stents having biodegradable layers
US20100211164A1 (en) * 2007-04-17 2010-08-19 Mcclain James B Stents having biodegradable layers
US20100228348A1 (en) * 2007-05-25 2010-09-09 Micell Technologies, Inc. Polymer Films for Medical Device Coating
US20100239635A1 (en) * 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
US20100241220A1 (en) * 2009-03-23 2010-09-23 Mcclain James B Peripheral Stents Having Layers
US20100256746A1 (en) * 2009-03-23 2010-10-07 Micell Technologies, Inc. Biodegradable polymers
US20100256748A1 (en) * 2009-04-01 2010-10-07 Micell Technologies, Inc. Coated stents
US20100272778A1 (en) * 2007-04-17 2010-10-28 Micell Technologies, Inc. Stents having controlled elution
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
US20110159069A1 (en) * 2008-12-26 2011-06-30 Shaw Wendy J Medical Implants and Methods of Making Medical Implants
US20110190864A1 (en) * 2010-02-02 2011-08-04 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US20110238161A1 (en) * 2010-03-26 2011-09-29 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011130448A1 (en) * 2010-04-16 2011-10-20 Micell Technologies, Inc. Stents having controlled elution
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US9636309B2 (en) 2010-09-09 2017-05-02 Micell Technologies, Inc. Macrolide dosage forms

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534989T3 (en) 2010-07-01 2015-05-04 Euticals S.P.A. New inclusion complexes solid pharmaceutical water soluble and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrins
CN104525944A (en) * 2014-12-23 2015-04-22 北京理工大学 High-energy beam-ultrasonic composite additive manufacturing method for metal materials

Citations (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3087660A (en) * 1962-07-24 1963-04-30 Yankee Plasties Inc Two-step garment hanger
US3087860A (en) * 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US4326532A (en) * 1980-10-06 1982-04-27 Minnesota Mining And Manufacturing Company Antithrombogenic articles
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US5158986A (en) * 1991-04-05 1992-10-27 Massachusetts Institute Of Technology Microcellular thermoplastic foamed with supercritical fluid
US5243023A (en) * 1991-08-28 1993-09-07 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polyimides containing amide and perfluoroisopropylidene connecting groups
US5340614A (en) * 1993-02-11 1994-08-23 Minnesota Mining And Manufacturing Company Methods of polymer impregnation
US5342621A (en) * 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5356433A (en) * 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
US5569463A (en) * 1990-05-17 1996-10-29 Harbor Medical Devices, Inc. Medical device polymer
US5811032A (en) * 1995-09-19 1998-09-22 Mitsubishi Gas Chemical Company, Inc. Biodegradable water-soluble polymer
US5824049A (en) * 1995-06-07 1998-10-20 Med Institute, Inc. Coated implantable medical device
US5948020A (en) * 1995-05-01 1999-09-07 Sam Yang Co., Ltd. Implantable bioresorbable membrane and method for the preparation thereof
US5957975A (en) * 1997-12-15 1999-09-28 The Cleveland Clinic Foundation Stent having a programmed pattern of in vivo degradation
US6190699B1 (en) * 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6364903B2 (en) * 1999-03-19 2002-04-02 Meadox Medicals, Inc. Polymer coated stent
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6372246B1 (en) * 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
US6409716B1 (en) * 1989-12-15 2002-06-25 Scimed Life Systems, Inc. Drug delivery
US6414050B1 (en) * 1997-05-10 2002-07-02 University Of Nottingham Biofunctional polymers prepared in supercritical fluid
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6448315B1 (en) * 1999-02-17 2002-09-10 Bone Support Ab Method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof
US20020133072A1 (en) * 1999-09-10 2002-09-19 Guo-Bin Wang Graft polymerization of substrate surfaces
US6461644B1 (en) * 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US6506213B1 (en) * 2000-09-08 2003-01-14 Ferro Corporation Manufacturing orthopedic parts using supercritical fluid processing techniques
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
US20030031699A1 (en) * 2002-09-30 2003-02-13 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
US6521258B1 (en) * 2000-09-08 2003-02-18 Ferro Corporation Polymer matrices prepared by supercritical fluid processing techniques
US6524698B1 (en) * 1990-09-27 2003-02-25 Helmuth Schmoock Fluid impermeable foil
US20030088307A1 (en) * 2001-11-05 2003-05-08 Shulze John E. Potent coatings for stents
US20030125800A1 (en) * 2001-11-05 2003-07-03 Shulze John E. Drug-delivery endovascular stent and method for treating restenosis
US20030143315A1 (en) * 2001-05-16 2003-07-31 Pui David Y H Coating medical devices
US20030180376A1 (en) * 2001-03-02 2003-09-25 Dalal Paresh S. Porous beta-tricalcium phosphate granules and methods for producing same
US6627246B2 (en) * 2000-05-16 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Process for coating stents and other medical devices using super-critical carbon dioxide
US20030185964A1 (en) * 2002-03-28 2003-10-02 Jan Weber Method for spray-coating a medical device having a tubular wall such as a stent
US20030204238A1 (en) * 2002-04-26 2003-10-30 Eugene Tedeschi Coated stent with crimpable coating
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6710059B1 (en) * 1999-07-06 2004-03-23 Endorecherche, Inc. Methods of treating and/or suppressing weight gain
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
US6736996B1 (en) * 1997-10-10 2004-05-18 North Carolina State University Compositions for protecting civil infrastructure
US20040106982A1 (en) * 1999-03-16 2004-06-03 Jalisi Marc M. Multilayer stent
US6749902B2 (en) * 2002-05-28 2004-06-15 Battelle Memorial Institute Methods for producing films using supercritical fluid
US6756084B2 (en) * 2002-05-28 2004-06-29 Battelle Memorial Institute Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions
US6755871B2 (en) * 1999-10-15 2004-06-29 R.R. Street & Co. Inc. Cleaning system utilizing an organic cleaning solvent and a pressurized fluid solvent
US20040126542A1 (en) * 2002-07-29 2004-07-01 Nitto Denko Corporation Pressure-sensitive adhesive tape or sheet
US6767558B2 (en) * 2000-03-10 2004-07-27 Pfizer Inc. Inhibiting oxidative degradation of pharmaceutical formulations
US6780475B2 (en) * 2002-05-28 2004-08-24 Battelle Memorial Institute Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions
US20040193262A1 (en) * 2003-03-29 2004-09-30 Shadduck John H. Implants for treating ocular hypertension, methods of use and methods of fabrication
US20040193177A1 (en) * 2003-03-31 2004-09-30 Houghton Michael J. Modified delivery device for coated medical devices
US6838528B2 (en) * 2001-01-19 2005-01-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US6837611B2 (en) * 2001-12-28 2005-01-04 Metal Industries Research & Development Centre Fluid driven agitator used in densified gas cleaning system
US6838089B1 (en) * 1998-04-14 2005-01-04 Astrazeneca Ab Antigen delivery system and method of production
US20050004661A1 (en) * 2001-01-11 2005-01-06 Lewis Andrew L Stens with drug-containing amphiphilic polymer coating
US20050003074A1 (en) * 1996-11-13 2005-01-06 Phoqus Pharmaceuticals Limited Method and apparatus for the coating of substrates for pharmaceutical use
US20050010275A1 (en) * 2002-10-11 2005-01-13 Sahatjian Ronald A. Implantable medical devices
US20050015046A1 (en) * 2003-07-18 2005-01-20 Scimed Life Systems, Inc. Medical devices and processes for preparing same
US20050019747A1 (en) * 2002-08-07 2005-01-27 Anderson Daniel G. Nanoliter-scale synthesis of arrayed biomaterials and screening thereof
US20050049694A1 (en) * 2003-08-07 2005-03-03 Medtronic Ave. Extrusion process for coating stents
US6868123B2 (en) * 2001-12-07 2005-03-15 Motorola, Inc. Programmable motion estimation module with vector array unit
US20050069630A1 (en) * 2003-09-30 2005-03-31 Advanced Cardiovascular Systems, Inc. Stent mandrel fixture and method for selectively coating surfaces of a stent
US20050079274A1 (en) * 2003-10-14 2005-04-14 Maria Palasis Method for coating multiple stents
US6884377B1 (en) * 1996-08-27 2005-04-26 Trexel, Inc. Method and apparatus for microcellular polymer extrusion
US6884823B1 (en) * 1997-01-16 2005-04-26 Trexel, Inc. Injection molding of polymeric material
US6897205B2 (en) * 2001-01-31 2005-05-24 Roehm Gmbh & Co. Kg Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
US6905555B2 (en) * 2001-02-15 2005-06-14 Micell Technologies, Inc. Methods for transferring supercritical fluids in microelectronic and other industrial processes
US20050147734A1 (en) * 2004-01-07 2005-07-07 Jan Seppala Method and system for coating tubular medical devices
US20050177223A1 (en) * 2003-09-18 2005-08-11 Palmaz Julio C. Medical devices having MEMs functionality and methods of making same
US20050175772A1 (en) * 2004-02-10 2005-08-11 Robert Worsham Apparatus and method for electrostatic spray coating of medical devices
US20050191491A1 (en) * 2003-04-08 2005-09-01 Yulu Wang Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process
US6939569B1 (en) * 1998-06-19 2005-09-06 Oxibio, Inc. Medical device having anti-infective and contraceptive properties
US20050196424A1 (en) * 2003-05-02 2005-09-08 Chappa Ralph A. Medical devices and methods for producing the same
US20050216075A1 (en) * 2003-04-08 2005-09-29 Xingwu Wang Materials and devices of enhanced electromagnetic transparency
US20050238829A1 (en) * 2004-04-22 2005-10-27 John Motherwell Differentially coated medical devices, system for differentially coating medical devices, and coating method
US20060020325A1 (en) * 2004-07-26 2006-01-26 Robert Burgermeister Material for high strength, controlled recoil stent
US20060094744A1 (en) * 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US20060121089A1 (en) * 2002-03-20 2006-06-08 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US20060134211A1 (en) * 2004-12-16 2006-06-22 Miv Therapeutics Inc. Multi-layer drug delivery device and method of manufacturing same
US20060136041A1 (en) * 2004-12-17 2006-06-22 Schmid Eric V Slide-and-lock stent
US20060193886A1 (en) * 2002-11-13 2006-08-31 Owens Gary K Medical devices with nanoporous layers and topcoats
US20060198868A1 (en) * 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
US20060222756A1 (en) * 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US7163715B1 (en) * 2001-06-12 2007-01-16 Advanced Cardiovascular Systems, Inc. Spray processing of porous medical devices
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US20070123977A1 (en) * 2000-03-15 2007-05-31 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20070196423A1 (en) * 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
US20070203569A1 (en) * 2006-02-24 2007-08-30 Robert Burgermeister Implantable device formed from polymer blends having modified molecular structures
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20080075753A1 (en) * 2006-09-25 2008-03-27 Chappa Ralph A Multi-layered coatings and methods for controlling elution of active agents
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US20080206304A1 (en) * 2007-02-27 2008-08-28 Boston Scientific Scimed, Inc. Medical devices having polymeric regions based on styrene-isobutylene copolymers
US20080213464A1 (en) * 2007-01-03 2008-09-04 Boston Scientific Scimed, Inc. Methods of applying coating to the inside surface of a stent
US20080255510A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20090105809A1 (en) * 2007-10-19 2009-04-23 Lee Michael J Implantable and lumen-supporting stents and related methods of manufacture and use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US7455688B2 (en) * 2004-11-12 2008-11-25 Con Interventional Systems, Inc. Ostial stent

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3087860A (en) * 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US3087660A (en) * 1962-07-24 1963-04-30 Yankee Plasties Inc Two-step garment hanger
US4326532A (en) * 1980-10-06 1982-04-27 Minnesota Mining And Manufacturing Company Antithrombogenic articles
US4733665B1 (en) * 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US6409716B1 (en) * 1989-12-15 2002-06-25 Scimed Life Systems, Inc. Drug delivery
US5569463A (en) * 1990-05-17 1996-10-29 Harbor Medical Devices, Inc. Medical device polymer
US6524698B1 (en) * 1990-09-27 2003-02-25 Helmuth Schmoock Fluid impermeable foil
US5158986A (en) * 1991-04-05 1992-10-27 Massachusetts Institute Of Technology Microcellular thermoplastic foamed with supercritical fluid
US5356433A (en) * 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
US5243023A (en) * 1991-08-28 1993-09-07 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polyimides containing amide and perfluoroisopropylidene connecting groups
US5342621A (en) * 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5340614A (en) * 1993-02-11 1994-08-23 Minnesota Mining And Manufacturing Company Methods of polymer impregnation
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5948020A (en) * 1995-05-01 1999-09-07 Sam Yang Co., Ltd. Implantable bioresorbable membrane and method for the preparation thereof
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US5824049A (en) * 1995-06-07 1998-10-20 Med Institute, Inc. Coated implantable medical device
US5811032A (en) * 1995-09-19 1998-09-22 Mitsubishi Gas Chemical Company, Inc. Biodegradable water-soluble polymer
US6461644B1 (en) * 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US6884377B1 (en) * 1996-08-27 2005-04-26 Trexel, Inc. Method and apparatus for microcellular polymer extrusion
US20050003074A1 (en) * 1996-11-13 2005-01-06 Phoqus Pharmaceuticals Limited Method and apparatus for the coating of substrates for pharmaceutical use
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
US6884823B1 (en) * 1997-01-16 2005-04-26 Trexel, Inc. Injection molding of polymeric material
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6414050B1 (en) * 1997-05-10 2002-07-02 University Of Nottingham Biofunctional polymers prepared in supercritical fluid
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US6736996B1 (en) * 1997-10-10 2004-05-18 North Carolina State University Compositions for protecting civil infrastructure
US5957975A (en) * 1997-12-15 1999-09-28 The Cleveland Clinic Foundation Stent having a programmed pattern of in vivo degradation
US6838089B1 (en) * 1998-04-14 2005-01-04 Astrazeneca Ab Antigen delivery system and method of production
US6190699B1 (en) * 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
US6939569B1 (en) * 1998-06-19 2005-09-06 Oxibio, Inc. Medical device having anti-infective and contraceptive properties
US6372246B1 (en) * 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6448315B1 (en) * 1999-02-17 2002-09-10 Bone Support Ab Method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof
US20040106982A1 (en) * 1999-03-16 2004-06-03 Jalisi Marc M. Multilayer stent
US6364903B2 (en) * 1999-03-19 2002-04-02 Meadox Medicals, Inc. Polymer coated stent
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6710059B1 (en) * 1999-07-06 2004-03-23 Endorecherche, Inc. Methods of treating and/or suppressing weight gain
US20020133072A1 (en) * 1999-09-10 2002-09-19 Guo-Bin Wang Graft polymerization of substrate surfaces
US6755871B2 (en) * 1999-10-15 2004-06-29 R.R. Street & Co. Inc. Cleaning system utilizing an organic cleaning solvent and a pressurized fluid solvent
US6767558B2 (en) * 2000-03-10 2004-07-27 Pfizer Inc. Inhibiting oxidative degradation of pharmaceutical formulations
US20070123977A1 (en) * 2000-03-15 2007-05-31 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US6627246B2 (en) * 2000-05-16 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Process for coating stents and other medical devices using super-critical carbon dioxide
US6506213B1 (en) * 2000-09-08 2003-01-14 Ferro Corporation Manufacturing orthopedic parts using supercritical fluid processing techniques
US6521258B1 (en) * 2000-09-08 2003-02-18 Ferro Corporation Polymer matrices prepared by supercritical fluid processing techniques
US20060222756A1 (en) * 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
US20050004661A1 (en) * 2001-01-11 2005-01-06 Lewis Andrew L Stens with drug-containing amphiphilic polymer coating
US6838528B2 (en) * 2001-01-19 2005-01-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US6897205B2 (en) * 2001-01-31 2005-05-24 Roehm Gmbh & Co. Kg Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
US6905555B2 (en) * 2001-02-15 2005-06-14 Micell Technologies, Inc. Methods for transferring supercritical fluids in microelectronic and other industrial processes
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
US20030180376A1 (en) * 2001-03-02 2003-09-25 Dalal Paresh S. Porous beta-tricalcium phosphate granules and methods for producing same
US20030143315A1 (en) * 2001-05-16 2003-07-31 Pui David Y H Coating medical devices
US7163715B1 (en) * 2001-06-12 2007-01-16 Advanced Cardiovascular Systems, Inc. Spray processing of porous medical devices
US20030088307A1 (en) * 2001-11-05 2003-05-08 Shulze John E. Potent coatings for stents
US20030125800A1 (en) * 2001-11-05 2003-07-03 Shulze John E. Drug-delivery endovascular stent and method for treating restenosis
US6868123B2 (en) * 2001-12-07 2005-03-15 Motorola, Inc. Programmable motion estimation module with vector array unit
US6837611B2 (en) * 2001-12-28 2005-01-04 Metal Industries Research & Development Centre Fluid driven agitator used in densified gas cleaning system
US20060121089A1 (en) * 2002-03-20 2006-06-08 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US20030185964A1 (en) * 2002-03-28 2003-10-02 Jan Weber Method for spray-coating a medical device having a tubular wall such as a stent
US20030204238A1 (en) * 2002-04-26 2003-10-30 Eugene Tedeschi Coated stent with crimpable coating
US6780475B2 (en) * 2002-05-28 2004-08-24 Battelle Memorial Institute Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions
US6756084B2 (en) * 2002-05-28 2004-06-29 Battelle Memorial Institute Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions
US6749902B2 (en) * 2002-05-28 2004-06-15 Battelle Memorial Institute Methods for producing films using supercritical fluid
US20040126542A1 (en) * 2002-07-29 2004-07-01 Nitto Denko Corporation Pressure-sensitive adhesive tape or sheet
US20050019747A1 (en) * 2002-08-07 2005-01-27 Anderson Daniel G. Nanoliter-scale synthesis of arrayed biomaterials and screening thereof
US20030031699A1 (en) * 2002-09-30 2003-02-13 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
US20050010275A1 (en) * 2002-10-11 2005-01-13 Sahatjian Ronald A. Implantable medical devices
US20060193886A1 (en) * 2002-11-13 2006-08-31 Owens Gary K Medical devices with nanoporous layers and topcoats
US20060193890A1 (en) * 2002-11-13 2006-08-31 Owens Gary K Method for loading nanoporous layers with therapeutic agent
US20040193262A1 (en) * 2003-03-29 2004-09-30 Shadduck John H. Implants for treating ocular hypertension, methods of use and methods of fabrication
US20040193177A1 (en) * 2003-03-31 2004-09-30 Houghton Michael J. Modified delivery device for coated medical devices
US20050216075A1 (en) * 2003-04-08 2005-09-29 Xingwu Wang Materials and devices of enhanced electromagnetic transparency
US20050191491A1 (en) * 2003-04-08 2005-09-01 Yulu Wang Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process
US20050196424A1 (en) * 2003-05-02 2005-09-08 Chappa Ralph A. Medical devices and methods for producing the same
US20080118543A1 (en) * 2003-05-08 2008-05-22 Advanced Cardiovascular Systems, Inc. Stent Coatings comprising hydrophilic additives
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050015046A1 (en) * 2003-07-18 2005-01-20 Scimed Life Systems, Inc. Medical devices and processes for preparing same
US20050049694A1 (en) * 2003-08-07 2005-03-03 Medtronic Ave. Extrusion process for coating stents
US20050177223A1 (en) * 2003-09-18 2005-08-11 Palmaz Julio C. Medical devices having MEMs functionality and methods of making same
US20050069630A1 (en) * 2003-09-30 2005-03-31 Advanced Cardiovascular Systems, Inc. Stent mandrel fixture and method for selectively coating surfaces of a stent
US20050079274A1 (en) * 2003-10-14 2005-04-14 Maria Palasis Method for coating multiple stents
US20050147734A1 (en) * 2004-01-07 2005-07-07 Jan Seppala Method and system for coating tubular medical devices
US20050175772A1 (en) * 2004-02-10 2005-08-11 Robert Worsham Apparatus and method for electrostatic spray coating of medical devices
US20050238829A1 (en) * 2004-04-22 2005-10-27 John Motherwell Differentially coated medical devices, system for differentially coating medical devices, and coating method
US20060020325A1 (en) * 2004-07-26 2006-01-26 Robert Burgermeister Material for high strength, controlled recoil stent
US20060094744A1 (en) * 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US20060134211A1 (en) * 2004-12-16 2006-06-22 Miv Therapeutics Inc. Multi-layer drug delivery device and method of manufacturing same
US20060136041A1 (en) * 2004-12-17 2006-06-22 Schmid Eric V Slide-and-lock stent
US20060198868A1 (en) * 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US20070196423A1 (en) * 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
US20070203569A1 (en) * 2006-02-24 2007-08-30 Robert Burgermeister Implantable device formed from polymer blends having modified molecular structures
US20080075753A1 (en) * 2006-09-25 2008-03-27 Chappa Ralph A Multi-layered coatings and methods for controlling elution of active agents
US20080255510A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080213464A1 (en) * 2007-01-03 2008-09-04 Boston Scientific Scimed, Inc. Methods of applying coating to the inside surface of a stent
US20080206304A1 (en) * 2007-02-27 2008-08-28 Boston Scientific Scimed, Inc. Medical devices having polymeric regions based on styrene-isobutylene copolymers
US20090105809A1 (en) * 2007-10-19 2009-04-23 Lee Michael J Implantable and lumen-supporting stents and related methods of manufacture and use

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8298565B2 (en) 2005-07-15 2012-10-30 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US20090123515A1 (en) * 2005-07-15 2009-05-14 Doug Taylor Polymer coatings containing drug powder of controlled morphology
US8758429B2 (en) 2005-07-15 2014-06-24 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US9827117B2 (en) 2005-07-15 2017-11-28 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US20090186069A1 (en) * 2006-04-26 2009-07-23 Micell Technologies, Inc. Coatings Containing Multiple Drugs
US9737645B2 (en) 2006-04-26 2017-08-22 Micell Technologies, Inc. Coatings containing multiple drugs
US9415142B2 (en) 2006-04-26 2016-08-16 Micell Technologies, Inc. Coatings containing multiple drugs
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US20100030261A1 (en) * 2006-10-02 2010-02-04 Micell Technologies, Inc. Surgical Sutures Having Increased Strength
US8636767B2 (en) 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US20080095919A1 (en) * 2006-10-23 2008-04-24 Mcclain James B Holder For Electrically Charging A Substrate During Coating
US20100063580A1 (en) * 2007-01-08 2010-03-11 Mcclain James B Stents having biodegradable layers
US9737642B2 (en) * 2007-01-08 2017-08-22 Micell Technologies, Inc. Stents having biodegradable layers
US20100272778A1 (en) * 2007-04-17 2010-10-28 Micell Technologies, Inc. Stents having controlled elution
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US9486338B2 (en) 2007-04-17 2016-11-08 Micell Technologies, Inc. Stents having controlled elution
US9775729B2 (en) 2007-04-17 2017-10-03 Micell Technologies, Inc. Stents having controlled elution
US20100211164A1 (en) * 2007-04-17 2010-08-19 Mcclain James B Stents having biodegradable layers
US20100228348A1 (en) * 2007-05-25 2010-09-09 Micell Technologies, Inc. Polymer Films for Medical Device Coating
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
US9789233B2 (en) 2008-04-17 2017-10-17 Micell Technologies, Inc. Stents having bioabsorbable layers
US20090292351A1 (en) * 2008-04-17 2009-11-26 Micell Technologies, Inc. Stents having bioabsorbable layers
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US20100015200A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug Delivery Medical Device
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20110159069A1 (en) * 2008-12-26 2011-06-30 Shaw Wendy J Medical Implants and Methods of Making Medical Implants
US20100239635A1 (en) * 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
US20100241220A1 (en) * 2009-03-23 2010-09-23 Mcclain James B Peripheral Stents Having Layers
US20100256746A1 (en) * 2009-03-23 2010-10-07 Micell Technologies, Inc. Biodegradable polymers
US20100256748A1 (en) * 2009-04-01 2010-10-07 Micell Technologies, Inc. Coated stents
US20110190864A1 (en) * 2010-02-02 2011-08-04 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US9687864B2 (en) 2010-03-26 2017-06-27 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US20110238161A1 (en) * 2010-03-26 2011-09-29 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011130448A1 (en) * 2010-04-16 2011-10-20 Micell Technologies, Inc. Stents having controlled elution
US9636309B2 (en) 2010-09-09 2017-05-02 Micell Technologies, Inc. Macrolide dosage forms

Also Published As

Publication number Publication date Type
WO2007011708A2 (en) 2007-01-25 application
WO2007011708A3 (en) 2007-06-28 application
WO2007011708A8 (en) 2007-04-26 application
US20160015537A1 (en) 2016-01-21 application

Similar Documents

Publication Publication Date Title
US6074135A (en) Coating or ablation applicator with debris recovery attachment
Sargeant et al. Covalent functionalization of NiTi surfaces with bioactive peptide amphiphile nanofibers
Debenedetti et al. Rapid expansion of supercritical solutions (RESS): fundamentals and applications
US6143370A (en) Process for producing polymer coatings with various porosities and surface areas
Jaworek et al. Electrospraying route to nanotechnology: an overview
Chen et al. A novel drug-eluting stent spray-coated with multi-layers of collagen and sirolimus
US20060088567A1 (en) Method of manufacturing a medical device having a porous coating thereon
US20080286440A1 (en) Process for coating a substrate
Tom et al. Precipitation of poly (L-lactic acid) and composite poly (L-lactic acid)-pyrene particles by rapid expansion of supercritical solutions
US6258733B1 (en) Method and apparatus for misted liquid source deposition of thin film with reduced mist particle size
US6860907B1 (en) Method of particle formation
US20070278103A1 (en) Nanoparticle coating of surfaces
US7951428B2 (en) Electrospray coating of objects
Reverchon et al. Production of antibiotic micro-and nano-particles by supercritical antisolvent precipitation
US20050070989A1 (en) Medical devices having porous layers and methods for making the same
US20070212547A1 (en) Method of powder coating medical devices
WO1997018341A1 (en) Nanostructured feeds for thermal spray
Leeuwenburgh et al. In vitro and in vivo reactivity of porous, electrosprayed calcium phosphate coatings
US20130270355A1 (en) Pressure based liquid feed system for suspension plasma spray coatings
Dove et al. A comparison of two contact angle measurement methods and inverse gas chromatography to assess the surface energies of theophylline and caffeine
US20090118823A1 (en) Endoprosthesis with porous reservoir
US20100256746A1 (en) Biodegradable polymers
WO2007127363A2 (en) Coatings containing multiple drugs
US20010022988A1 (en) Device and method for protecting medical devices during a coating process
WO1995001324A1 (en) Salmeterol xinafoate with controlled particle size

Legal Events

Date Code Title Description
AS Assignment

Owner name: MICELL TECHNOLOGIES, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAYLOR, DOUG;DEYOUNG, JAMES;MCCLAIN, JIM;REEL/FRAME:021102/0582;SIGNING DATES FROM 20080611 TO 20080613